alpha-Galactosidase Assay Kit Price
Product Description: Fabry disease, an inherited multisystem disorder, is a lysosomal storage disease that is caused by mutations in the GLA
gene, which encodes alpha-galactosidase A. The enzyme normally breaks down a fatty substance called globotriaosylceramide, which is a type of
sphingoglycolipids important for the function of cells and tissues. Failure to turn over the sphingolipid causes accumulation of
globotriaosylceramide in the lysosomes and hence sphingolipidosis. Beginning in childhood, this buildup causes many symptoms affecting many
parts of the body. Features of Fabry disease may include episodes of pain, angiokeratomas, hypohidrosis, corneal opacity, G.I. malfunction, and
etc. Potentially life-threatening complications such as stroke, kidney damage, and heart attack can occur. Recombinant alpha-GAL protein is
being used as therapy for the disease. The alpha-galactosidase (alpha-GAL) assay is based on the hydrolysis of
4-nitrophenyl-alpha-D-galactopyranoside. Cleavage of pNA from the substrate increases absorbance at 405 nm (extinction coefficient= 18
mM-1cm-1), allowing for sensitive and quantitative assay of alpha-galactosidase enzyme activity present in tissue/cell lysates and biological fluids.
Kit components are stable for at least 1 year if stored and handled properly.
Kit Components:
alpha-Galactosidase Assay Solution: 10 ml, store at -20ºC (for 100 wells)
alpha-Galactosidase Control Solution: 10 ml, store at 4ºC
10x Cell Lysis Solution: 25 ml, store at 4ºC
MSDS: TX-100, 2-mercaptoethanol, 4-nitrophenyl-alpha-D-galactopyranoside
Related kits: GAA Assay, beta-Galactosidase Assay
Product Description: Fabry disease, an inherited multisystem disorder, is a lysosomal storage disease that is caused by mutations in the GLA
gene, which encodes alpha-galactosidase A. The enzyme normally breaks down a fatty substance called globotriaosylceramide, which is a type of
sphingoglycolipids important for the function of cells and tissues. Failure to turn over the sphingolipid causes accumulation of
globotriaosylceramide in the lysosomes and hence sphingolipidosis. Beginning in childhood, this buildup causes many symptoms affecting many
parts of the body. Features of Fabry disease may include episodes of pain, angiokeratomas, hypohidrosis, corneal opacity, G.I. malfunction, and
etc. Potentially life-threatening complications such as stroke, kidney damage, and heart attack can occur. Recombinant alpha-GAL protein is
being used as therapy for the disease. The alpha-galactosidase (alpha-GAL) assay is based on the hydrolysis of
4-nitrophenyl-alpha-D-galactopyranoside. Cleavage of pNA from the substrate increases absorbance at 405 nm (extinction coefficient= 18
mM-1cm-1), allowing for sensitive and quantitative assay of alpha-galactosidase enzyme activity present in tissue/cell lysates and biological fluids.
Kit components are stable for at least 1 year if stored and handled properly.
Kit Components:
alpha-Galactosidase Assay Solution: 10 ml, store at -20ºC (for 100 wells)
alpha-Galactosidase Control Solution: 10 ml, store at 4ºC
10x Cell Lysis Solution: 25 ml, store at 4ºC
MSDS: TX-100, 2-mercaptoethanol, 4-nitrophenyl-alpha-D-galactopyranoside
Related kits: GAA Assay, beta-Galactosidase Assay
 | |  | |  | |  | |  | |  | |  | |  | |  | |  | |  |
Biomedical Research Service
& Clinical Application
& Clinical Application